Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Cannabinoids in the treatment of rheumatic diseases: Pros and cons.

Sarzi-Puttini P, Ablin J, Trabelsi A, Fitzcharles MA, Marotto D, Häuser W.

Autoimmun Rev. 2019 Dec;18(12):102409. doi: 10.1016/j.autrev.2019.102409. Epub 2019 Oct 21. Review.

PMID:
31648042
2.

Fibromyalgia as a chronic primary pain syndrome: issues to discuss.

Häuser W, Clauw D, Fitzcharles MA.

Pain. 2019 Nov;160(11):2651-2652. doi: 10.1097/j.pain.0000000000001686. No abstract available.

PMID:
31626074
3.

Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria.

Wolfe F, Butler SH, Fitzcharles M, Häuser W, Katz RL, Mease PJ, Rasker JJ, Russell AS, Russell IJ, Walitt B.

Scand J Pain. 2019 Dec 18;20(1):77-86. doi: 10.1515/sjpain-2019-0054.

PMID:
31596726
4.

Upregulation of cortical GABAA receptor concentration in fibromyalgia.

Pomares FB, Roy S, Funck T, Feier NA, Thiel A, Fitzcharles MA, Schweinhardt P.

Pain. 2020 Jan;161(1):74-82. doi: 10.1097/j.pain.0000000000001707.

5.

Factors associated with waiting times for persons with rheumatic conditions in multidisciplinary pain treatment facilities.

Deslauriers S, Roy JS, Bernatsky S, Feldman DE, Pinard AM, Desmeules F, Fitzcharles MA, Perreault K.

J Pain Res. 2019 Jul 30;12:2379-2390. doi: 10.2147/JPR.S206519. eCollection 2019.

6.

Medical cannabis: strengthening evidence in the face of hype and public pressure.

Fitzcharles MA, Shir Y, Häuser W.

CMAJ. 2019 Aug 19;191(33):E907-E908. doi: 10.1503/cmaj.190509. No abstract available.

PMID:
31427354
7.

Cannabis for rheumatic pain: hope or hype?

Hazlewood GS, Niaki OZ, Fitzcharles MA.

Clin Rheumatol. 2019 Oct;38(10):2655-2657. doi: 10.1007/s10067-019-04658-3. Epub 2019 Jul 5. No abstract available.

PMID:
31278513
8.

Altered microbiome composition in individuals with fibromyalgia.

Minerbi A, Gonzalez E, Brereton NJB, Anjarkouchian A, Dewar K, Fitzcharles MA, Chevalier S, Shir Y.

Pain. 2019 Nov;160(11):2589-2602. doi: 10.1097/j.pain.0000000000001640.

PMID:
31219947
9.

Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials.

Häuser W, Welsch P, Klose P, Radbruch L, Fitzcharles MA.

Schmerz. 2019 Oct;33(5):424-436. doi: 10.1007/s00482-019-0373-3.

PMID:
31073761
10.

Response to Wolfe. Letter to the Editor, "Fibromyalgia Criteria".

Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, Fitzcharles MA, Paiva ES, Staud R, Sarzi-Puttini P, Buskila D, Macfarlane GJ.

J Pain. 2019 Jun;20(6):741-742. doi: 10.1016/j.jpain.2019.02.003. Epub 2019 Feb 26. No abstract available.

PMID:
30822536
11.

Fibromyalgia syndrome: under-, over- and misdiagnosis.

Häuser W, Sarzi-Puttini P, Fitzcharles MA.

Clin Exp Rheumatol. 2019 Jan-Feb;37 Suppl 116(1):90-97. Epub 2019 Feb 8. Review.

12.

Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases.

Fitzcharles MA, Niaki OZ, Hauser W, Hazlewood G; Canadian Rheumatology Association.

J Rheumatol. 2019 May;46(5):532-538. doi: 10.3899/jrheum.181120. Epub 2019 Jan 15.

PMID:
30647183
13.

Medical Cannabis for Older Patients.

Minerbi A, Häuser W, Fitzcharles MA.

Drugs Aging. 2019 Jan;36(1):39-51. doi: 10.1007/s40266-018-0616-5. Review.

PMID:
30488174
14.

AAPT Diagnostic Criteria for Fibromyalgia.

Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, Fitzcharles MA, Paiva ES, Staud R, Sarzi-Puttini P, Buskila D, Macfarlane GJ.

J Pain. 2019 Jun;20(6):611-628. doi: 10.1016/j.jpain.2018.10.008. Epub 2018 Nov 16. Review.

15.

Dr. Fitzcharles and Dr. Shir reply.

Fitzcharles MA, Shir Y.

J Rheumatol. 2018 Jul;45(7):1071. doi: 10.3899/jrheum.180043. No abstract available.

PMID:
29961682
16.

Facts and myths pertaining to fibromyalgia.

Häuser W, Fitzcharles MA.

Dialogues Clin Neurosci. 2018 Mar;20(1):53-62. Review.

17.

Comorbid fibromyalgia: A qualitative review of prevalence and importance.

Fitzcharles MA, Perrot S, Häuser W.

Eur J Pain. 2018 Oct;22(9):1565-1576. doi: 10.1002/ejp.1252. Epub 2018 Jun 22. Review.

PMID:
29802812
18.

Diagnostic confounders of chronic widespread pain: not always fibromyalgia.

Häuser W, Perrot S, Sommer C, Shir Y, Fitzcharles MA.

Pain Rep. 2017 Apr 30;2(3):e598. doi: 10.1097/PR9.0000000000000598. eCollection 2017 May. Review.

19.

Medical cannabis: A forward vision for the clinician.

Fitzcharles MA, Eisenberg E.

Eur J Pain. 2018 Mar;22(3):485-491. doi: 10.1002/ejp.1185. Epub 2018 Jan 29. Review.

PMID:
29377381
20.

The Perils of Overestimating the Efficacy of Cannabis-Based Medicines for Chronic Pain Management.

Hauser W, Fitzcharles MA.

Pain Physician. 2018 Jan;21(1):E79-E80. No abstract available.

21.

Attitudes Toward and Management of Fibromyalgia: A National Survey of Canadian Rheumatologists and Critical Appraisal of Guidelines.

Agarwal A, Oparin Y, Glick L, Fitzcharles MA, Adachi JD, Cooper MD, Gallo L, Wong L, Busse JW.

J Clin Rheumatol. 2018 Aug;24(5):243-249. doi: 10.1097/RHU.0000000000000679.

PMID:
29280818
22.

Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - An overview of systematic reviews.

Häuser W, Petzke F, Fitzcharles MA.

Eur J Pain. 2018 Mar;22(3):455-470. doi: 10.1002/ejp.1118. Epub 2017 Oct 15.

PMID:
29034533
23.

Cannabinoids in Pain Management and Palliative Medicine.

Häuser W, Fitzcharles MA, Radbruch L, Petzke F.

Dtsch Arztebl Int. 2017 Sep 22;114(38):627-634. doi: 10.3238/arztebl.2017.0627. Review.

24.

Unravelling Fibromyalgia-Steps Toward Individualized Management.

Häuser W, Perrot S, Clauw DJ, Fitzcharles MA.

J Pain. 2018 Feb;19(2):125-134. doi: 10.1016/j.jpain.2017.08.009. Epub 2017 Sep 21.

PMID:
28943233
25.

Pain management: Opioids for RA: a clinical dilemma.

Häuser W, Fitzcharles MA.

Nat Rev Rheumatol. 2017 Sep;13(9):521-522. doi: 10.1038/nrrheum.2017.123. Epub 2017 Aug 3. No abstract available.

PMID:
28769111
26.

Another Nasty Effect of Opioids: Attenuating the Benefits of Motivational Interviewing in Fibromyalgia?

Fitzcharles MA, Shir Y.

J Rheumatol. 2017 Apr;44(4):407-409. doi: 10.3899/jrheum.170076. No abstract available.

PMID:
28604346
27.

Impact of Moving From a Widespread to Multisite Pain Definition on Other Fibromyalgia Symptoms.

Dean LE, Arnold L, Crofford L, Bennett R, Goldenberg D, Fitzcharles MA, Paiva ES, Staud R, Clauw D, Sarzi-Puttini P, Jones GT, Ayorinde A, Flüß E, Beasley M, Macfarlane GJ.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1878-1886. doi: 10.1002/acr.23214. Epub 2017 Nov 2.

28.

Management of fibromyalgia: practical guides from recent evidence-based guidelines.

Häuser W, Ablin J, Perrot S, Fitzcharles MA.

Pol Arch Intern Med. 2017 Jan 4;127(1):47-56. doi: 10.20452/pamw.3877. Epub 2017 Jan 4. Review.

29.

Histological Underpinnings of Grey Matter Changes in Fibromyalgia Investigated Using Multimodal Brain Imaging.

Pomares FB, Funck T, Feier NA, Roy S, Daigle-Martel A, Ceko M, Narayanan S, Araujo D, Thiel A, Stikov N, Fitzcharles MA, Schweinhardt P.

J Neurosci. 2017 Feb 1;37(5):1090-1101. doi: 10.1523/JNEUROSCI.2619-16.2016. Epub 2016 Dec 16.

30.

2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria.

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B.

Semin Arthritis Rheum. 2016 Dec;46(3):319-329. doi: 10.1016/j.semarthrit.2016.08.012. Epub 2016 Aug 30.

PMID:
27916278
31.

Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis.

Ste-Marie PA, Shir Y, Rampakakis E, Sampalis JS, Karellis A, Cohen M, Starr M, Ware MA, Fitzcharles MA.

Pain. 2016 Dec;157(12):2792-2797.

PMID:
27842047
32.

Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases.

Fitzcharles MA, Häuser W.

Curr Rheumatol Rep. 2016 Dec;18(12):76. doi: 10.1007/s11926-016-0625-5. Review.

PMID:
27832442
33.

Dr. Fitzcharles, et al, reply.

Fitzcharles MA, Ste-Marie PA, Rampakakis E, Sampalis JS, Shir Y.

J Rheumatol. 2016 Nov;43(11):2077. No abstract available.

PMID:
27803347
34.

Cannabinoids for fibromyalgia.

Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W.

Cochrane Database Syst Rev. 2016 Jul 18;7:CD011694. doi: 10.1002/14651858.CD011694.pub2. Review.

35.

Treat-to-Target Strategy for Fibromyalgia: Opening the Dialogue.

Häuser W, Clauw DJ, Fitzcharles MA.

Arthritis Care Res (Hoboken). 2017 Apr;69(4):462-466. doi: 10.1002/acr.22970. Epub 2017 Feb 28. Review. No abstract available.

36.

Attitudes of Israeli Rheumatologists to the Use of Medical Cannabis as Therapy for Rheumatic Disorders.

Ablin JN, Elkayam O, Fitzcharles MA.

Rambam Maimonides Med J. 2016 Apr 19;7(2). doi: 10.5041/RMMJ.10239.

37.

Pain Management for the Young Adult Rheumatology Patient in an Era of Medicinal Marijuana Legalization.

Fitzcharles MA, Hazel EM, Taylor G, Tucker LB.

J Rheumatol. 2016 Apr;43(4):686-8. doi: 10.3899/jrheum.150103. No abstract available.

PMID:
27037241
38.

Disability in Fibromyalgia Associates with Symptom Severity and Occupation Characteristics.

Fitzcharles MA, Ste-Marie PA, Rampakakis E, Sampalis JS, Shir Y.

J Rheumatol. 2016 May;43(5):931-6. doi: 10.3899/jrheum.151041. Epub 2016 Mar 15.

PMID:
26980580
40.

Medical use of cannabis products: Lessons to be learned from Israel and Canada.

Ablin J, Ste-Marie PA, Schäfer M, Häuser W, Fitzcharles MA.

Schmerz. 2016 Feb;30(1):3-13. doi: 10.1007/s00482-015-0083-4.

PMID:
26767992
41.

Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials.

Fitzcharles MA, Ste-Marie PA, Häuser W, Clauw DJ, Jamal S, Karsh J, Landry T, Leclercq S, Mcdougall JJ, Shir Y, Shojania K, Walsh Z.

Arthritis Care Res (Hoboken). 2016 May;68(5):681-8. doi: 10.1002/acr.22727. Review.

42.

Real-life assessment of the validity of patient global impression of change in fibromyalgia.

Rampakakis E, Ste-Marie PA, Sampalis JS, Karellis A, Shir Y, Fitzcharles MA.

RMD Open. 2015 Sep 14;1(1):e000146. doi: 10.1136/rmdopen-2015-000146. eCollection 2015. Erratum in: RMD Open. 2015;1(1):e000146corr1.

43.

Comparison of Physician-Based and Patient-Based Criteria for the Diagnosis of Fibromyalgia.

Wolfe F, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, Mease PJ, Russell AS, Jon Russell I, Walitt B.

Arthritis Care Res (Hoboken). 2016 May;68(5):652-9. doi: 10.1002/acr.22742.

44.

Is a Responsive Default Mode Network Required for Successful Working Memory Task Performance?

Čeko M, Gracely JL, Fitzcharles MA, Seminowicz DA, Schweinhardt P, Bushnell MC.

J Neurosci. 2015 Aug 19;35(33):11595-605. doi: 10.1523/JNEUROSCI.0264-15.2015.

45.

Multidisciplinary treatment for rheumatic pain.

Kudrina I, Shir Y, Fitzcharles MA.

Best Pract Res Clin Rheumatol. 2015 Feb;29(1):156-63. doi: 10.1016/j.berh.2015.04.029. Epub 2015 May 29. Review.

PMID:
26267009
46.

Pregabalin for chronic pain: does one medication fit all?

Giladi H, Choinière M, Fitzcharles MA, Ware MA, Tan X, Shir Y.

Curr Med Res Opin. 2015;31(7):1403-11. doi: 10.1185/03007995.2015.1040750. Epub 2015 May 11.

PMID:
25868712
47.

Fibromyalgia.

Häuser W, Ablin J, Fitzcharles MA, Littlejohn G, Luciano JV, Usui C, Walitt B.

Nat Rev Dis Primers. 2015 Aug 13;1:15022. doi: 10.1038/nrdp.2015.22. Review.

PMID:
27189527
48.

Re: Harth M, Neilson WR. Fibromyalgia and disability adjudication: no simple solutions to a complex problem. Pain Res Manag 2014;19(6):293-299.

Fitzcharles MA, Ste-Marie PA, Mailis A, Shir Y.

Pain Res Manag. 2014 Nov-Dec;19(6):300-1. No abstract available.

49.

Adjudication of fibromyalgia syndrome: challenges in the medicolegal arena.

Fitzcharles MA, Ste-Marie PA, Mailis A, Shir Y.

Pain Res Manag. 2014 Nov-Dec;19(6):287-92.

50.

Management of fibromyalgia in older adults.

Fitzcharles MA, Ste-Marie PA, Shir Y, Lussier D.

Drugs Aging. 2014 Oct;31(10):711-9. doi: 10.1007/s40266-014-0210-4. Review.

PMID:
25227451

Supplemental Content

Loading ...
Support Center